In short
Podcast Summary: CNBC's "Fast Money" - Episode on International Investing and NIH Funding Cuts
- Episode Title: International Investing Vs. U.S… And NIH Funding Cuts Impact On Drug Development
- Air Date: March 17, 2025
- Host: Melissa Lee
- Guests: Tim Seymour, Karen Feinerman, Dan Nathan, Guy Adami, Rebecca Patterson (former chief strategist at Bridgewater), John Flavin (founder and CEO of Portal Innovations)
Overview The episode discusses the significant outperformance of international markets compared to the U.S. markets in 2025 and the implications of potential NIH funding cuts on drug development. The conversation is driven by insights from the roundtable of traders and industry experts, reflecting on investment strategies and the broader economic landscape.
Key Segments
- International vs. U.S. Markets
- Current Trends:
- Emerging market stocks have substantially outperformed the S&P 500 in early 2025 (EEM ETF up 8%, S&P down 3.5%).
- Traders debate whether to invest domestically or internationally.
- Trader Opinions:
- Tim Seymour: Advocates for international investments, citing factors like a weakening dollar and fiscal dynamics in Europe. He emphasizes long-term potential in markets like China, Brazil, and Europe.
- Karen Feinerman: Supports staying invested in international markets but expresses caution about a potential pullback.
- Dan Nathan: Offers a more balanced view, suggesting shorting international against U.S. markets in the near term amid concerns of a slowing economy.
- Insights on China:
- Discussion on China’s focus on consumer stimulation through fiscal policy and implications for companies like Baidu and Alibaba.
- NIH Funding Cuts and Drug Development
- Impact on Research:
- NIH cuts affecting long-term research projects, including a 30-year diabetes study, raise concerns about the future of drug development.
- A study highlights NIH's critical role in funding FDA-approved drugs.
- Expert Opinions:
- John Flavin: Warns that cuts threaten innovation and may drive research overseas, emphasizing the historical significance of NIH funding in advancing medical research.
- Focus on the potential negative effects on various disease categories, particularly cancer and Alzheimer's.
- Market Dynamics & Predictions
- Short-Term Predictions:
- Rebecca Patterson: Suggests that while Europe may offer opportunities, the upcoming April tariffs could pose challenges. Advocates for a defensive investment strategy in the near term.
- Sector Analysis:
- Emphasis on the tech and healthcare sectors, with mentions of potential opportunities in European infrastructure given recent government spending trends.
- Company-Specific News
- NVIDIA Conference: Anticipation builds around NVIDIA’s AI conference, with speculation about product announcements impacting stock performance.
- Affirm’s Challenges: Discussion on Affirm's drop due to competition from Klarna, considerations about the buy now, pay later market amidst consumer spending downturns.
- Intel's Rally: Notable increase in Intel shares following news of its new CEO and potential strategic changes.
Conclusion The episode encapsulates the complexities of international investing versus domestic strategies in a volatile economic landscape while shedding light on the critical implications of NIH funding cuts on drug innovation. The traders’ insights and expert opinions provide listeners with a comprehensive understanding of current market dynamics and future investment opportunities.
---
Key Takeaways
- Emerging markets are currently outperforming the U.S., prompting traders to consider where to allocate investments.
- NIH funding cuts could have dire consequences for drug development, impacting everything from startups to major pharmaceutical companies.
- The potential for a weaker dollar may create favorable conditions for international investments, although upcoming tariffs could complicate this outlook.
Next Steps for Investors
- Consider reallocating portions of investment portfolios towards emerging markets and sectors benefiting from fiscal policies.
- Stay informed on developments related to NIH funding and its broader impact on the biotech and pharmaceutical industries.
- Monitor the outcomes of key industry events such as NVIDIA’s AI conference for potential market movements.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the Nasdaq market site in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. The international divide. Emerging market stocks have been far outperforming the S &P this year. But can the group keep its leadership in a game of would you rather? We find out where the traders would put their money right now. Plus, we're counting down to NVIDIA's big AI conference. What to expect from the GTC keynote tomorrow. What it could mean for the stock. And later, a firm drops as a soon-to-be public competitor scoops up a big deal. Netflix streaming higher on one big bull call on Wall Street.
0:35and inside Intel's best three-day rally in over 37 years. I'm Melissa Lee, coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Feinerman, Dan Nathan, and Guy Adami. We start off with what has become a rare two-day win for stocks, with major markets following up Friday's rally with more gains to kick off the week. The Dow up 350 points, the S &P 500 gaining over 0.5%. The NASDAQ getting within 75 points of the 18 ,000 level. All had been down earlier in the session, But even with today's gains, U.S. markets are far underperforming the rest of the world. The EEM emerging markets ETF up more than 8 % in 2025, while the S &P is down 3.5%.
1:16China, Brazil, Europe, Mexico, and Japan all outperforming the U.S. so far this year. This divergence got us wondering, at these levels, would you rather put money to work at home or abroad? And I'll go to our emerging markets specialist, Timothy Seymour. Well, you know, there's no question for me. I'd rather be abroad, not only because I'm the ambassador, but I also run an international ETF, iDevo, which was the I in Blysep last year. I just think that there's a lot of different reasons why this trade isn't just a two-week trade. And I think that's the debate for people. It's been – it's actually not a two-week trade.
1:52It's probably – if you look at the outperformance, DAX outperformed the S &P by 25 percent since Thanksgiving. But I'm going to coin Dan Likes is – what is it? The fateful eight. Fateful eight. So I'm going with I'm going with MIGA, which is make international great again. And it's with some irony that the rest of the world has really been rallying since this administration took office. And I think it's a it's a combination of the dollar is going to get weaker. I think there might even be like a mini Plaza Accord. Take your your history book out for people if you don't know what that reference is.
2:23But the fiscal dynamic out of Europe is important. I think deep seek was a very important event for the world. I think it's certainly beneficial to China, but I think it's beneficial to Europe. I think if you get a Ukraine deal, leave the politics aside of that. I think energy costs in Europe go way down. I think the dynamics for deregulation in Europe are very important. But you started all this with a 15-year relative underperformance. That is something that doesn't change overnight. And you can make an argument that you're starting to see this trade work bits and parts of the last couple of years.
2:51So the valuations offer you a really attractive upside, even here as a discount to the U.S. You have better dividend yields, and I think you have fiscal policy as a tailwind. Is this trade, though, really working because U.S. tech has been under pressure? And in Europe, for instance, right, it's underweighted tech relative to the United States. It's really been benefiting from the presence of industrials and banks, the things that had been going in the rally, even here in the United States. So are you saying that the tech money leaving just one of the places going? If the tech trade is back on, maybe the money doesn't come back.
3:21I mean, I've had on various international for a while, and the only one of really any significant size is China. The rest is just little EWG and DXJ, which is actually yen adjusted. But so I'm feeling a little underweighted, rest of the world. But I feel like, oh, my God. Yes, right. That's how we got here. It's just what it is. All the money flowing into a market that doesn't have the market cap to absorb it. It's just going to go up. But I feel like, God, this has been such a big move. Maybe we do see a little pullback, and I'll have to jump in anyway. God, you're smart. No, I don't. Well, no, because he's going Plaza Court.
4:03That's where you're going. Yeah, come on. No, but I hearken back to Las Vegas like eight or nine, ten years ago. When we went to Las Vegas. We went out, and we were just sort of hanging out collectively, and somebody approached us and said, is there an emerging market specialist amongst us staring straight at Tim Seymour? It's one of the highlights of the. I didn't pay anybody for that. That was legit. I mean, you know, there are people that want to know. Of course they do. Especially now. Never know. Especially now. With all that said, yeah, I agree with Tim. I mean, I think you definitely want to stay there.
4:33We talked about EWZ at the end of January, and look at how well that's performed. That's the Brazil ETF, by the way. And a weaker dollar is going to win there. And quite frankly, that's about to break through about a 15-year downtrend that we've been in. And FXI, say what you want, but now you're talking three-year highs, and I think that's got a lot of room left as well. I'm going to trade the globe here a little bit. We're just getting it in here. You know, I think a good pairs trade at this moment on a short-term basis would be shorting international along the U.S. I mean, my base case is kind of that all of this chaos that we've absorbed over the last couple of months and is doing a number on the markets because the markets are anticipating the potential for a slowdown here if we were in a full-scale trade war.
5:12I suspect that doesn't happen. I suspect as we get into mid-April, we get back to that kind of base case scenario. And that certainly happens if the market continues to go down because it worries a bit more of a slowing economy based on the policy. So to me, I think the U.S. is probably more interesting at this point. And I think we'll probably test those recent lows, the 5500 level from Friday at some point. And you may have a really good opportunity to kind of average into this trade as it relates to the U.S. The one thing I'll say is in China, there are some opportunities. If you look at like a Baidu, OK, they get the predominant amount of their sales from search related advertising.
5:46But we know what this model looks like. It looks a lot like Google. They have a video site. They have a cloud business that's growing fast. And they have Ernie. Yeah, they do. The AI. Oh, yeah. The AI. Oh, yeah. And so I just, I think a name like this. Maybe they can pull up a five-year of this. It looks a lot like Alibaba before it just took off. So to me, I think, like, you're going to find interesting opportunities, especially with all that stimulus. But I wouldn't hold your breath for this stimulus to kind of give the Chinese economy a huge bump because it hasn't over the last few years. But this is the stock.
6:16I'm sorry. Famous Ernie's for 100. Well, Bernie, Bernie and Ernie show at University of Tennessee. That, of course, yeah. Ernie Grunfeld. Ernie Grunfeld. Ernie and Ernie. Ernie on three's company. I mean, I don't know. Well, that's 506 here. Hi. Hi. 506. We have a lot of wood to chop here. Let's chop in terms of what China announced, though, because we had been talking about this huge press conference. There was a huge run up on Friday in terms of the expectations for the stimulus. The mandate to raise incomes, especially for farmers, it seems like a much more a bigger effort to directly stimulate the consumer than efforts past, which is sort of it went through the financial system in order to trickle down to the consumer.
6:59But you have to you have to give them credit for trying something different. And there's no question that your traditional infrastructure build out is not going to work here. You know, what I would get back to where I do think that, I mean, Dan's referencing this with Baidu. If you look at their tech sector and you look at the transformation that you've had, I mean policy towards their own companies, towards their national champion companies. And then you listen to the companies themselves. I mean, when you listen to Baba, this is the B in tube, right? It is. Congrats. It's about time. It's also the A in carb.
7:29Look, and it was the B in zebra, correct? Yeah, but that's the last year. And the B in blicep was last year. So Dan and I were early in the trade, which means we were wrong. But when you listen to even what Baba tells you is they're going to spend 10 times more on CapEx towards AI and cloud in the next three years than they have over the last decade, decade and a half. So the spend is there, certainly in other parts of the economy. And it gets you back to where if you believe China is looking to be competitive on a global stage in technology, I think some of these companies are going to be allowed to do what they want to do.
7:59That's why. I mean, again, the movement of Alibaba, which is relentless. And again, I think this is something that also you can you can see where global players who don't have to be in China. And again, this is something where my ETF, we didn't have to own this for a while. And we've owned it now for two or three months. But I don't think it's time to sell, Baba. I think the valuation is an argument to stay there. I agree with that. And the crux of a lot of this emerging market, and Tim will speak to this, is a weaker U.S. dollar, which, by the way, I think will continue. You know, here the administration want for lower rates.
8:27Well, if they get lower rates, they're going to get a weaker dollar as well, which, by the way, is something quietly they all probably want. Because when you have a$37 trillion debt problem, you want that currency to be weaker. And I think that's what you're going to be seeing more of. I think that's why these emerging markets trades are going to work out as well as they have been and will continue to. All right. For more on what is next for international markets, let's bring in Rebecca Patterson, former chief strategist at Bridgewater. Rebecca, great to see you. Great to see all of you. Happy St.
8:55Patrick's. Happy St. Patrick's. Nice screen there you got on. In terms of allocating, you know, the next dollar, would it be to U.S. or would it be abroad? If I'm looking at a one week or two week trade, probably abroad. But I I'm a little surprised you all haven't spent more of this first six minutes on the April 2nd tariffs that are coming that are going to be bigger than what we've seen to date and are going to be aimed at the rest of the world. That doesn't mean that we can't see a decoupling continue for some time, but it is going to be a pretty big headwind I take your point so earlier China's tilt in this latest stimulus towards the consumer is a pretty big deal It's not big in size, but it's big philosophically for president xi to actually say, okay, we're going to help the consumer The other thing they said they're going to help is technology and the stock market And we know historically China has used state-related bodies to intervene and support their own market.
9:52So even if they get hit with tariffs, do they do enough there to provide an offset? And maybe this is a low volatility but a stable-ish place to be while we go through this policy uncertainty. Maybe. I am nervous about the rest of the world being able to decouple on a sustained basis. I think what we've seen so far, primarily profit taking on the U.S., repatriation, foreigners taking their toys home. Their capital went home, and that's what weakened the dollar and lifted those markets. I think that's been the biggest factor driving this trade. That's finite. Once they rebalance, it's done unless we continue to get new positive catalysts.
10:30So in your view, it is uncertain as to whether or not Germany's stimulus plan will outweigh the negative impacts from tariffs, for instance, or China stimulus will outweigh the negative impacts? The German stimulus, I think, is actually a much bigger deal than what we're seeing in China, relatively speaking. What they're doing is a structural break from history by loosening the fiscal constraints, allowing the government to spend significantly more money, especially in defense and infrastructure. And what we know from history is when governments do this targeted fiscal stimulus, it doesn't get priced in all at once because the capital keeps rolling out over a period of years.
11:08So I do think there is a sustainable trade in European infrastructure and defense. It won't go in a straight line, but it probably has some legs to it. I mean, years, not quarters or weeks. China, I'm a little less certain about because they have so many structural headwinds, demographics just being one of them. And the tariffs are just going to make sustaining this latest bounce hard. We can spend a whole hour on the plaza accord and the possible new version of that. I don't know if the viewers today want to spend a whole hour with us on it, but that's a whole other can of worms. Rebecca, it's Karen.
11:44Let me go back to Germany, because this is such a massive shift, right? So you talk about for the next week or two, but I mean, it's a much, much bigger shift than that. Can you isolate where you would think about Germany versus some of the rest of the European markets? Yeah. So, you know, if come April 2nd And around that date, we get this new wave of tariffs. That's obviously going to include Europe. President Trump has made that very clear. And you get a pullback in some of these markets in Europe. That might be an opportunity to average into a long position. In terms of where I'd go in Europe, look, over the next 6, 12 months, personally, I'd rather be a little bit more on the defensive side.
12:25So looking across Europe, markets like Switzerland and the UK tend to have lower betas. They tend to be a little less volatile, a little more defensive. And they also offer the valuations and lack of ownership that the rest of Europe does. Germany itself, though, I would be looking for any dips in some of those big infrastructure companies, things like Arine Mattel, which I know has already rallied a lot. But just as an example, those sorts of companies that will benefit from this spending in the years to come, I think it will have legs. just like the Chips and Science Act, just like the Highway Act in the 1950s in the U.S.
13:02and defense in the 1980s. These things ran for years. We talked about a weaker dollar. What is your sort of take on the dollar going forward? Because the drop we've seen has been pretty precipitous in a very short period of time. Yes, precipitous. That's a good one. I'm happy that I was able to actually pronounce that right after you. So, you know, again, I think the dollar falling is less about what's happening in the U.S. and more about the capital flow leaving the U.S. for the rest of the world, including Europe and China. And if that rebalancing continues, the dollar weakness can continue.
13:36Foreigners had put a lot of money into the U.S. over the last few years. So there is money to keep leaving. But if they think that the U.S. could still do OK and they still want that tech exposure, they might not want to take a lot more out. The other thing I'd worry about, and we have the FOMC meeting this week. Yes, this week already. Goodness. And if the Fed starts saying they're a little more nervous about inflation expectations rising and they decide that they don't want to have two rate cuts priced in for the rest of this year, that's a signal. And if inflation keeps Fed funds on pause longer than the market's expecting, that's going to provide a measure of support for the dollar.
14:14I think the dollar is more of a range bound situation in the next few months than straight down from here, frankly. We started the segment off, Rebecca, asking the ultimate question, the ultimate would you rather, and that is U.S. or Europe. It really sounds like if you had your druthers, you would say none of the above, because it sounds like you really want to be extremely defensive, at least in the near term, with fixed income and gold, correct? That's correct. I mean, look, later this year, we are going to get a tax package through in the U.S. It is going to be incrementally stimulative, although not to the same degree as what we saw in 2017, early 2018.
14:50We're going to have much bigger tariffs. That's going to be a drag. Immigration, I think, is going to be a drag on growth. So I think for the U.S. market, we're starting from a great point, right? We had strong growth at the end of last year, strong consumer balance sheets. But I think we're going to be seeing moderation in growth. And so equities might have a positive return this year, but it's going to be single digit, not double digit. You can have some exposure overseas. to be diversified. But then I also, even at these levels, I still would be looking to have a small position in gold, small position in fixed income, and probably looking to the degree it's appropriate at actively managed hedge funds to give you some more of that diversification.
15:27Because I think we're going to be in for a wild ride this year. There's a lot of big policy initiatives underway. And frankly, some of them, if they go through, are unprecedented. Rebecca, always great to see you. Thank you. Thanks. Rebecca Patterson. All right. So what do you take away from the conversation? By the way, we've been wordsmithing very well tonight, as we often do. So I just want to add one that I think tops them all. I mean, what's going on in Germany, it's more than extraordinary. It's epical. Okay. Epical? Is that a real word? It's not just epic? E-P-E-C-H-O. Yes. No, it's not epical.
15:59It's O-C-H. I was asking. Just asking. Epic. E-P-O-C-H. Oh, epical. Yeah, okay. Oh, she's just corrected me. Well, that's from your Catholic school teachings on Sundays. I don't know if that's the way you pronounce it. Anyway, proceed, please. So what's going on in Europe is really fiscal, and I think that's part of it. But then if you look at what's outperformed this year, even over here, you could look at an XLV. So in other words, health care. But look at a Novartis. Look at a Sanofi. And then as you get into the industrials, it's not just Siemens. I mean, you have Infion, and then you have some technology companies that are really exposed to this, like SAP.
16:33So, you know, I just think that there are companies on their own merit that valuation make a lot of sense here. It doesn't mean that, yeah, it's been a huge run, and I think we don't know what's going to happen April 2nd. Meantime, NVIDIA closing well off its lows of the session, but still ending the day in the red, the worst performer in the SMH semiconductor ETF today. The company holds its AI GTC conference this week with a keynote from CEO Jensen Huang tomorrow. Investors awaiting updates on its Blackwell GPU and its next-gen Rubin chip. Shares still down 22 % from record highs hit in January.
17:04Over the last week, three analysts have lowered their price targets on the stock. So are expectations prices to sell the news, Dan? If it is sell the news, then watch out for the entire general AI trade. Because, again, we all thought good quarters, good guidance. Just your acronym. Yeah, the Gen 8. Yeah, exactly. And I played that game right. You know, I mean, listen, it sold off after the results. The stock was already down, right? There was a lot of negative sentiment. A lot of their customers had already sold off over the prior couple weeks. So I just don't know if there's anything new for them to talk about as far as the product roadmap exists right now.
17:37So I'd be most worried if the stock, let's say, rallies because it's been down a lot and then fails because that is just meaning that there's no appetite for this story right now. Or what is the incremental buyer looking for? So we were talking about this the other day. I'm more interested in what are they seeing right now, not what is a little bit down the road. What are they seeing right now? Has the story changed? You know, we come back to this. Is there going to be a lot more compute needed for inference? And is DeepSeq actually potentially a plus? Right. CapEx story. What is it? You know, again, CapEx is not written in stone.
18:10If companies decide, you know what, the environment is not so we don't view it as favorable. There's too much ambiguity out there. They'll pull back on CapEx. NVIDIA loses to that, I think. That and the fact that they promised in the back half of this year to see a reacceleration of margins. Let's see if they address that as well. It is amazing that after hearing all of the major hyperscalers come out and raise their CapEx guidance, that there is still disbelief around those numbers, right? That there's still, in investors' minds, an asterisk next to any number given by a meta, a Google, whoever.
18:41And remember, those numbers and that guidance was well after DeepSeek. They had a chance to recant or try to hedge their words or something. So I think it's important. I think everyone's saying the same thing, though, that this is an important point for the market. It's a period where the breakdown in semis has been very clear, and it goes all the way back to last summer. Invitic traded the best of all of them, as it should. It's not expensive, but this is an important moment. So to the asterisk that you just mentioned, I mean, they just gave us the guidance. They're not going to change anything, right?
19:14So if anything, like if they were to come out and be a bit more bullish about that CapEx guidance or like upgrade their guidance for the quarter or something, no one would believe it because they had the opportunity on February 26th to do that, and nothing's really changed. The other thing I'd say about the asterisk is that, you know, these stocks that got killed in 2022, Meta was down 70 % at the lows in October 2022. That stock did not start rallying until they started cutting costs and still they started firing people. They have rationalized their costs as it relates to hiring. The only thing that they'd be able to cut if the stocks were down a lot over the next few months or a year or something would be their CapEx.
19:49And that's how these companies do that. I mean, we're not, we've talked about this for years and years, you know what I mean? Like when you're spending too much on CapEx, but your revenue's slow a little bit, then there's something that has to be reacclimated. And again, you know, like we saw why all these stocks sold off after their earnings, Microsoft, Meta, Amazon, and Google, because their revenue had decelerated and they hadn't laid off that CapEx guidance. If anything, they raised it. By the way, our own Jim Cramer is speaking with NVIDIA CEO Jensen Huang live from the GTC conference on Wednesday.
20:19That's at 1015 Eastern return time on Swap on the Street with even more on mad money. Coming up, a retail replacement, Walmart, shaking things up in the buy now, pay later space. News that had shares of Affirm sinking today and what it could mean for what will be the newest stock in the space. The details next. Plus, it's not just fintech. EV leaders facing increased competition as well. How one Chinese automaker is electrifying the space in just five minutes. We'll explain when Fast Money returns.
20:50This is Fast Money with Melissa Lee right here on CNBC.
21:03Welcome back to Fast Money. Buy now, pay later. Stock affirmed falling nearly 16 percent on its lows after CNBC reported rival Klarna would take over a key partnership with Walmart. The stock recovered some of the losses, but still ended the day down more than 4%. Klarna, which on Friday filed plans to go public, will provide loans to Walmart customers in stores and online through the retailers' one pay in the coming weeks. I know Karen had been interested in Affirm leading up to this. So it was down a lot on this. But as you know, you read the 8K, Affirm said, you know, it was 5 % of GMV. It was only 2%, right, of adjusted operating income.
21:39So that's not so big. And apparently we don't know this because Klarna doesn't need to update their S1 right now that there was a lot of equity incentive. So the Walmart would get equity in in Klarna and that would probably be, you know, valuable. So how much was it really worth to to a firm if they had to go along at price the way it was priced at Klarna? Not enough. I find this really interesting. It's come back a long, long way. It had that huge run, two huge quarters. I'm going to let the dust settle a little, but I like Affirm. Yeah, I just say this. You've got to figure out what else is going on here.
22:18So this is a huge boon for Klarna before they go public. We saw this with Reddit. Remember they did this deal with Google, and that really made sure that the numbers were going to work out of the gate. So, you know, were they competing on price? What did they have to give up? This is Klarna. At the end of the day, though, for Affirm, this is a big knock, you know. I mean, like we've seen this again with Amazon. It was like, you know, we thought that, well, why wouldn't they buy them? Well, why buy the cow when you get the milk for free? So, you know, this is a space that you think is perfect for a Walmart customer, right, especially on some of the bigger items.
Read the full transcript
22:47So, again, I find it interesting more for Klarna than I do. The last thing I'll say is last year, one of the first stories that we heard about use cases for generative AI, Klarna said they fired 700 customer service workers. Maybe they have some edge in the way they're integrating this technology. But to your point about the IPO, though, sorry. I mean, you want to really this is a PR. I don't know that it's a stunt per se, but you would take on this business. It's a very nice thing to announce as you hit the road. That's what I meant. Why do you want to leave all the stunts? Why do you want to be in this space right now at a time when the consumer is stepping down and the valuation makes no sense?
23:22I mean, this company maybe becomes profitable in 2025. It's a great company. And all we hear about is how nimble they are in the credit space. But they've never gone through what we could be seeing. And maybe we don't. I mean, credit spreads haven't really credit spreads have basically indicated that the equity markets once again are wrong, or at least that's what credit markets usually tell equity markets. But you can't tell me and retail sales today was a step down in spending. I just like why do I want to own five times sales going into a period where the consumer is clearly weakening and we don't even know what's going on?
23:52Coaching point. Yeah, I think we could see buy now, pay later become even bigger as the consumer is stressed. And they signed this deal for Sixth Street to do funding. That was a really important deal. So I think also they've had these two quarters where they turned the corner. I think it's interesting. Stock's down 50 % in a little over a month, number one. Tim's right in everything he said, but if you're looking for a bounce, this is a level traded four times normal volume today, traded back down to those November levels. I actually think it traded okay today. There's a lot more fast Monday to come.
24:24Here's what's coming up next. Charged up and ready to go in just five minutes. how one Chinese EV maker is electrifying the space and the pressure it could put on the competition. Plus, pharma in focus amid potential cuts to NIH funding. What it would mean for drug development in the U.S. for years to come. Ahead, you're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.
24:58quick programming note the next fast money live event is coming up on june 5th in this turbulent and unsettled market come join us for this unique in-person experience right here at the nasdaq market site it's a chance to connect with the fast money traders ask questions get their perspective on how to navigate your investments in these topsy-turvy times you'll watch the show here at the NASDAQ, be part of an in-depth Q &A session with the traders, and then share what's on your mind over cocktails. You'll also walk out with a six-month subscription to CNBC Pro for new users and a special commemorative gift.
25:29So register for the next Fast Money Live. Scan the QR code on our screen or go to cnbcevents.com slash fastmoney. It was fun. It was a lot of fun. It was more than fun. It was an event. That was one of those things like you will remember that 10, 15 years from now. We had a blast and we drank tequila and we laughed a lot. But, I mean, we were building our top five stocks and also our top five rock and roll bands. I mean, we were getting to the stuff that matters. No, it was a chance to really talk to people personally, learn a little bit more about how they're investing and what they're doing in the markets.
25:59And, you know, obviously, it's probably never been more important to have that conversation. Yep. I'm sure you guys out there have a lot of questions. So come to June 5th. Ask them. Meantime, some electrifying news in the EV space. China's BYD unveiling a new charging system that it says can power up cars in just five minutes. The company's chairman and founder saying the system is capable of providing 470 kilometers or 292 miles of range, and it tests on its new sedan. BYD also saying it will build a charging network across China and begin selling cars with the new tech next month. Shares of American rival Tesla, meantime, down to start the week.
26:34Elon Musk's company coming off an eight-week losing streak, its longest on record, also got its price target slashed over at Mizuho earlier today. You pointed this one out. I mean, this this seems like, I mean, just another knock in China. Yeah. I mean, the headlines today were bad. I mean, Xiaomi, which has obviously been a four-mobile competitor to Apple over there on the smartphone. I mean, they supposedly have a really hot car that's going to come after the Tesla Model Y. Yeah. They're going to Europe. So I think that's huge. I think the Trump administration on the first day, they kind of cut funding for it from the IRA for the state, the electrifying station build out here in the U.S.
27:08And I just like listen, I can't say this enough. You know, the CEO who's not there last week, he tweeted out something on his other company that Stalin, Mao and Hitler did not murder millions of people. He retweeted that. OK, he said that I mean, like this is not talked about enough, people. I'm just telling you that this is one of like the most influential companies in the planet or was. And he's behaving like this on his other platform. And you guys could say, well, this is a show about stocks. This stock is being adversely affected by his behavior, and his behavior is downright despicable. I mean, a lot of what he's doing these days is alienating either current customers or future customers.
27:47And so it is our business to talk about that impact. Yeah, I mean, but you look at the stock, and I think that's what we're trying to do here. 220-ish is where this whole thing started in October before the election. We've almost round-tripped it. So if you're looking for a level to buy this stock for a trade, I think this is about as good as it gets. And there will be analysts that raise their price target on the back of the sell-off. We saw Adam Jonas do it a couple weeks ago. I think he has a$600 price target. So there are going to be some short-term catalysts. It doesn't mean it's fixed by any stretch, but you could easily see the stock go back to$275,$280, and nothing has changed.
28:20And there's a little more focus on the chair of the board, too, Robin Denham, and the$682 million in comp that she's had since 2014. But that is not – I'd rather talk about BYD. I'm actually long BYD and Idebo. and this is a company that really is, first of all, they're looking at building their third plan across Europe. They talked about Germany. They're trying to, and tariffs have everything to do with it. And again, their ability to access the European markets, and we know that actually growth has been slower in China. I mean, they're a global company. They're looking to see where they can grow.
28:47I like this one. Coming up, drug development in the crosshairs of the Trump administration's cost-cutting campaign. How NIH research funding cuts could impact everyone from big pharma to seed-stage startups when Fast Money returns. Back in two.
29:06Welcome back to Fast Money. Stocks building on Friday's rebound rally. The Dow up more than 350 points. The S &P up more than half a percent. The Nasdaq gaining about three-tenths of a percent. The indices each putting in their first back-to-back gains in a month. Gold meantime, higher again today, hitting another record high. That's its 12th record of the year. The precious metal is up nearly 14 percent in 2025. Energy also in the green crude at its highest level in about two weeks. The XLE Energy ETF leading the S &P 500 today. And shares of Alphabet taking a leg lower late in the session after the Wall Street Journal said it was back in talks to buy cyber startup Wiz for$30 billion.
29:42Previous deal talk stalled last year. That's a company that you're familiar with, Dan. Yeah, it's interesting that you're seeing this. Last year, they said no. They wanted to go public. This year, you know, they get a really good bump. We've been talking about this in the private market, some of these AI companies. the way that they've been skipping billions at a time in valuations in a very short period of time. But this is the sort of acquisition that really helps Google possibly take a bunch of share from some of their bigger incumbents in the space that would be Microsoft and be AWS. So, again, I also think it speaks a little bit to the fact that, you know, we haven't seen a lot of deals announced so far.
30:15And might this be one that they're willing to kind of test the waters with? Because Google has never made a deal of this size. I think in 2012 we were talking about Motorola Mobility was the last big one. and who the hell knows what happened to that one inside of Google. All right. Well, meantime, the NIH canceling funding for an ongoing 30-year study tracking patients with diabetes and prediabetes. It is the latest research project on the chopping block that's funding and personnel cuts grip the nation's health agencies. A 2023 paper in JAMA Health Forum finding that the NIH gave funding to 354 of the 356 drugs approved by the FDA from 2010 to 2019.
30:51So what do these cuts mean for the future of drug development? Portal Innovations founder and CEO, John Flavin, joins us for more. John, great to have you back. Thanks. Hi, Melissa. How are you? Good. This really does seem quite dire. I know that in the halls of many labs, research facilities across the country, scientists are worried that they're going to get their funding pulled and that all of the work that they put in for years will just be down the drain. Can you tell us how you think this will play out? Yeah. I mean, the model, you know, historically from when Vannevar Bush came on the scene in World War II to kind of really put the National Institutes of Health as a strategic priority.
31:29And that led to the Bayh-Dole Act, you know, which allowed universities to spin technologies into companies. It's really been the lifeblood for creating great companies that bring new drugs and new devices to patients. So, you know, this uncertainty is causing a freeze. And when that freeze takes place, you know, innovation is risked to going to other places. Innovation flows to money. And we want innovation to be in the United States. It's been the primary place for biopharma innovation, creating$90 billion in exports year over year. So it is the place to be and where the talent wants to be to create new innovations.
32:08And this kind of uncertainty really mixes things up and causes downstream effects for innovation for patients. I'm wondering if you're thinking of certain kinds of disease that will really suffer because of these cuts. The NIH, for instance, is the world's largest funder of cancer research. There's also 495 active clinical trials in Alzheimer's and related dementia funded by the NIH. These are just two areas that could really feel some impact. Yeah. And I mean, if you look from 1991 to date, cancer death rates have come down 33%. No doubt a big impact coming from NIH and all those innovators that move the needle for cancer patients in the present day.
32:53Look, HIV, you know, NIH was a primary source of innovation to drive a solution for that deadly disease. Human Genome Project leading to big discoveries in cancer, Alzheimer's, and more to come because of the investment that was made in that project. And then the present day, mRNA, as we know, you know, a very important tool for vaccines and the approach that can be used for deadly diseases like COVID and others that may come downstream. So major effects across every disease category and who's picking up the slack. I think you're going to see, you know, private industry move in. I mean, we certainly are interested, you know, in picking up the slack as it relates to early stage innovation from a venture capital perspective.
33:36but philanthropy states, you look at the state of Texas, they have the secret fund, $6 billion fund that invests directly into cancer startups and other innovation. So where will the money come from? Who will step into the breach? John, it's Tim. Thanks. Maybe China, maybe other parts of the world for sure will be stepping in. But I guess just get to the other side of this. I mean, is there any part of this that you think is justified? I mean, there's cuts going on everywhere and there's fat everywhere. So I don't think there's anybody sitting on this desk. And my guess is much of our audience at home wants to stop innovative technologies going on in medicine and in biotech.
34:12But drop it in the context of where we are seeing cuts. I mean, is any part of this justified? Well, like any type of endeavor, efficiency should always be reviewed. And, you know, maximizing efficiency and effectiveness is always something that should be done on behalf of the American taxpayer. That said, we've seen tremendous innovations over the past century that have benefited from NIH funding. And so it's difficult to say that these moves, particularly the confusion, like where are we going with this? What's the big vision? Tell us how this will make and maintain America as the place to be if you want to innovate and help patients downstream.
34:57If you can't sell that vision, then you're going to cause a lot of disruption in this space because people, investors, innovators, don't really know where to position themselves to be able to continue to carry the ball forward. So it's not a great situation. Certainly, universities can improve their translation rates. And certainly, pushing more of that out to the private sector may indeed have a benefit to taxpayers as we try to be more efficient in taking these great scientific breakthroughs. I mean, look at CRISPR. You know, this technology spun out, you know, Nobel laureate Jennifer Doudna.
35:33These types of technologies are at risk if we're not able to backfill that breach. John, it's Karen Feinerman. Thanks for being on. We had just put up a stat a little bit ago. One point four four billion dollars was the average NIH spend for first in class drugs. What was the overall spend for what those drugs would be? I'm trying to understand the NIH's role versus all the other, whether it's private or, you know, pharmaceutical companies or any other place that it gets funded. Well, I mean, billions of dollars are going in, you know, even just if you just take one drug, it requires, you know, upwards of 800 million, you know, sometimes lower, sometimes higher.
36:11And it's an eight to 10 year journey to go from the professor's lab all the way to the patient through the FDA approval process. So it's a long, expensive, and very risky process. If you look at what NIH has done, particularly on the Small Business Innovation Research Grant side of things, I mean, that's been the life's blood. It's kind of America's seed fund, if you will. They spend about a billion dollars a year in SBIR, Small Business Innovation Research, funding from NIH that has really spawned thousands of startups over the past several decades that have then gone on to raise private capital.
36:44For every$1 that the NIH has put into the research platform and initiative,$3 are seen in economic impact. So take that to scale, and it's massive. John, thanks so much for joining us on this very important topic. We appreciate it. My pleasure, Melissa. John Flavin of Portal Innovations. Coming up, analysts binging on Netflix shares getting a boost as one firm sees more than 15 % upside in the name. Why they say there is more monetization than meets the eye. The details in Fast Money Returns.
37:23Welcome back to Fast Money, a call of the day on Netflix. Moffitt Nathanson upgrading the streamer to a buy from neutral, raising the price target to$1 ,100. That's almost 16 % higher from today's close. Analysts say Netflix has, quote, won the streaming wars and then improved monetization will boost profits in the years to come. What do you think of this call, Guy? I'm sure they're saying, you know, I wish we did this a week or so ago. It doesn't matter. The timing is still pretty good. And I think they're right. If you pull up a long-term chart, you'll see. We've seen sell-offs of this magnitude before in Netflix over the years.
37:54And each time, three or four weeks later, the stock is ratcheting higher again. They win. Yeah, valuation may be a little expensive given what they've traded historically. But it's Netflix world, and I think they're going to get to their price target. They say the ad tier will drive margins without any ceiling in sight. That's a pretty bold call. Yeah, they're saying they can't build enough inventory for ads. That's a great problem to have, right? And then along with, you know, however many price increases there will be down the road, that just all falls to the bottom line. I'm surprised. They're great, Martha Nathanson.
38:26I'm surprised they weren't. Needed. Yeah. Look, it's hard to argue with the call. It was easy to see where Netflix was taking a significant pullback when other, you know, high-tech stocks that are part of passive investing in some of those indices. But it gets back to evaluation where, you know, we know they've won the streaming wars. We know their cash flow accretive. We know that actually their content spend is actually starting to go up in a good way. We also know that there's levers they haven't even pulled in terms of live events, not necessarily sports, but things that look like sports. And how about gaming?
38:58But I do think that if we start to see the consumer pull back, I don't think anybody's recession-proof. And I think Netflix would have exposure. Coming up, some fast movers catching our attention in today's session. The headlines behind the moves in Intel, Reddit, and Lululemon next. And do not miss a special Mad Money out west from NVIDIA's GTC conference. Jim is chatting with the CEOs of Intuit, Snowflake, Arm, Dell, and Cisco, plus a one-on-one with NVIDIA CEO Jensen Fong on Wednesday. That's all on Mad Money right here on CNBC. Meantime, more Fast Money in two.
39:34Welcome back to Fast Money. Some fast movers catching our eyes today. First up, Intel jumping nearly 7%. A regulatory filing on Friday showing incoming CEO Lipu Tan will buy$25 million in stock. Reuters also reporting that Tan is considering significant changes to Intel's chip manufacturing and AI strategies. Intel shares now up nearly 25 % since Thursday. Its best three-day run since October of 1987. Do you remember October of 1987? Yeah, I do. Check that now. Now, look at this is a non-doctored photo, but this is me in October. What are you laughing at? Are you arrested? What happened? I know.
40:14It looks like a mugshot. That's a Drexel burner. Did you steal Mark Bavaro's wallet? No, I didn't steal anything, Tim. Look, it's the same. I can make that same face right now. Watch. It's fantastic, isn't it? Can we do a side-by-side? I think you can probably. Yeah, we should. Split them up. Split them up. They can. You look like Mark Bavaro. See the way my eyes get dark? Like my mood. Is somebody from Georgetown? I think Intel could trade 34. That's the high in July of last year. We've said that for a while, and I've said if I could put an I in my tube, I would. But as I said, that would make it twee, but that's not a word.
40:46Could be iTunes. Could be. Like iPhone. Wild day for Reddit. Meantime, stock falling as much as 6.5 % early in the day after analysts at Redbird initiated the stock with a sell rating and a$75 price target, but they spiked higher midday on news. Google had expanded its partnership with the social media platform, rising as much as 11 percent, only to end the day down 2 percent. Reddit shares are up nearly 270 percent since their IPO about a year ago. I think this is the most times we've mentioned Reddit in one show in a long time. Yeah, I mean, listen, this thing has been a rocket ship. I never thought it would perform this way.
41:22When you think of some of the comps in the public markets, they just haven't been doing particularly well. So, you know, good on them to kind of get the strategy that they did get going. I think the Google deal that they did right before, it was pure margin. You know what I mean? So it was a great deal on their part. I just, you know, I have no sense how they're growing users or advertisers. But to me, it seems a little fairly valued. All right. Lululemon shares meantime surging more than 5 % today. Truist out with a bullish note, noting positive brand momentum on TikTok and saying the company can benefit from warmer weather.
41:49Still, shares are down almost 11 % so far in March. Anybody trading Lululemon here? Tim? Well, I like the call. I think the call was back a year ago that the competitive landscape was really rough and that there was going to be some impact to margin and they were going into a drawdown period with peak margins. I think some of those dynamics have worked through a bit in the stock price. I don't think it's terribly cheap, but I think you can nibble it. Up next, final trades.
42:25We'll be right back.
42:46and genre. Genre. Je m 'appelle Timothée.
42:53Target, Mel. Sorry. Thank you for watching Fast Money. Stay back here tomorrow. Five more Fast. Matt and Money Jim Cramer starts right now. Met non.
43:16on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
International markets have outperformed the U.S. in a big way this year, but will the trend continue into Q2? Where are out traders see the biggest global gains, and if they’re betting on more divergence between the markets. Plus NIH funding cuts putting drug development on the chopping block. The names feeling the impact, and what’s at stake in the pharma space.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
